June 16, 2022 Uncategorized Roche provides update on Alzheimer’s Prevention Initiative study evaluating crenezumab in autosomal dominant Alzheimer’s disease Read more
June 15, 2022 Acad, Gov/Utilities Life Science Tools PR/Corporate Roche receives FDA EUA for cobas SARS-CoV-2 Duo, the first PCR test to simultaneously detect COVID-19 and quantitatively measure viral load levels of COVID-19 Read more
June 10, 2022 Acad, Gov/Utilities Roche announces positive data from broad blood cancer portfolio at European Hematology Association Annual Meeting Read more
June 9, 2022 Acad, Gov/Utilities Clinical Research/Diagn. U.S. FDA approves Foundation Medicine’s FoundationOne®CDx as a companion diagnostic for Roche’s Rozlytrek® (entrectinib) Read more
June 9, 2022 Uncategorized European Commission approves Roche’s Tecentriq as adjuvant treatment for a subset of people with early-stage non-small cell lung cancer Read more
June 8, 2022 Uncategorized European Commission approves Roche’s first-in-class bispecific antibody Lunsumio for people with relapsed or refractory follicular lymphoma Read more
May 31, 2022 Acad, Gov/Utilities FDA approves Roche’s Evrysdi for use in babies under two months with spinal muscular atrophy (SMA) Read more
May 27, 2022 Clinical Research/Diagn. Product Launch New pivotal data demonstrate clinical benefit of Roche’s glofitamab, a potential first-in-class bispecific antibody for people with aggressive lymphoma Read more
May 27, 2022 Clinical Research/Diagn. Product Launch New pivotal data demonstrate clinical benefit of Roche’s glofitamab, a potential first-in-class bispecific antibody for people with aggressive lymphoma Read more
May 25, 2022 Uncategorized Roche’s Polivy combination approved by European Commission for people with previously untreated diffuse large B-cell lymphoma Read more
